Cytotherapy (journal)

Cytotherapy is a peer-reviewed medical journal covering the areas of cell and gene therapy. The journal was established in 1999 and is published by Elsevier on behalf of the International Society for Cell & Gene Therapy (ISCT). Cytotherapy is edited by Editor-in-Chief Edwin Horwitz, Managing Editor Kenneth W. Witwer, Commissioning Editor Patrick Hanley, and Assistant Editor Rachel Burga.

Cytotherapy

Discipline	Cell biology, immunology, stem cells
Language	English
Edited by	Edwin Horwitz
Publication details
Former name(s)	Cytokines, Cellular and Molecular Therapy; Cytokines and Molecular therapy
History	1999-present
Publisher	Elsevier on behalf of the International Society for Cell & Gene Therapy
Frequency	12/year
Impact factor	5.414 (2020)
Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt )
ISO 4	Cytotherapy
Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus · W&L
CODEN	CYTRF3
ISSN	1465-3249 (print) 1477-2566 (web)
LCCN	00243205
OCLC no.	288963798
Links
Journal homepage Online access Online archive

Aims and Scope

The Journal publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. Cytotherapy publishes articles exploring the following topics:

• Development and/or characterization of novel gene therapies and cell and/or extracellular vesicle (EV)-based therapeutics.
• Design of novel therapeutic approaches employing cell/EV/gene products.
• Mode of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.
• Identification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response rates.
• Role of stem/stromal cells and/or EVs in disease pathophysiology.
• Early and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapies.
• Important advances in cell/EV/gene-based product manufacturing and validation.
• Global/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapies.

Abstracting and indexing

This journal is abstracted and indexed in Science Citation Index Expanded, Current Contents/Clinical Medicine, Current Contents/ Life Sciences, BIOSIS Previews, and MEDLINE/PubMed. According to the Journal Citation Reports, the journal has a 2020 impact factor of 5.414.^[1]